<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001570</url>
  </required_header>
  <id_info>
    <org_study_id>970074</org_study_id>
    <secondary_id>97-C-0074</secondary_id>
    <nct_id>NCT00001570</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer</brief_title>
  <official_title>A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Bolus PSC 833 is administered on Day 1 simultaneously with initiation of 24 hour continuous&#xD;
      infusion of PSC 833, followed by another continuous infusion lasting an additional 6 days. To&#xD;
      ensure the safety of a 7 day infusion of PSC 833, one patient is treated for 5 days and a&#xD;
      second for 6 days, before the first cohort is enrolled.&#xD;
&#xD;
      Vinblastine is administered in escalating doses on days 2-5. At least 3 patients are entered&#xD;
      at each dose level. The MTD will be defined as the dose immediately below that at which 2&#xD;
      patients experience dose limiting toxicity.&#xD;
&#xD;
      Treatment continues every 28 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase I clinical trial of the combination of 120-hour continuous intravenous infusion of&#xD;
      vinblastine with oral PSC 833 has shown activity in patients with advanced malignancies,&#xD;
      particularly renal cell cancer. The MTD of vinblastine in combination with the oral drink&#xD;
      solution of PSC 833 was determined to be 0.9 mg/m2/day for five days and 12.5 mg/kg po q 12&#xD;
      hours for eight days, respectively. For the soft gel capsule formulation, the MTD was&#xD;
      determined to be 0.6 mg/m2/day vinblastine for five days and 4 mg/kg po q 6 hours PSC 833 for&#xD;
      eight days. Ataxia was the dose limiting toxicity. Of the 46 patients, two complete&#xD;
      remissions and one partial remission were seen among 29 patients with renal cell carcinoma.&#xD;
&#xD;
      In this Phase I study, patients with advanced renal carcinoma will be treated with escalating&#xD;
      doses of vinblastine given as a 72 hour infusion, starting at approximately 40% of the total&#xD;
      standard dose. A shorter infusion schedule of vinblastine was chosen since there is evidence&#xD;
      in other cytotoxic combinations that PSC 833 increases the AUC and decreases the plasma&#xD;
      clearance of chemotherapeutic agents by approximately twofold. Cytochrome P 450 3A or CYP3A,&#xD;
      which is the major cytochrome enzyme in the metabolism of vinblastine and PSC 833, will be&#xD;
      measured during the first and fourth cycle through an in vivo test using a single intravenous&#xD;
      dose of midazolam, a short-acting benzodiazepine. Vinblastine and PSC 833 pharmacokinetics&#xD;
      will be performed at the same time. For patients with accessible lesions, tumor biopsy will&#xD;
      be requested.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1997</start_date>
  <completion_date>January 2001</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>46</enrollment>
  <condition>Kidney Neoplasms</condition>
  <condition>Neoplasm Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PSC 833</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinblastine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
        Histologically proven renal cancer with clear cell component:&#xD;
&#xD;
        Measurable or evaluable disease;&#xD;
&#xD;
        No brain metastases;&#xD;
&#xD;
        No grade 2 or greater peripheral neuropathy or neurologic toxicity symptoms.&#xD;
&#xD;
        PRIOR/CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic Therapy: Not specified.&#xD;
&#xD;
        Chemotherapy: No prior or concurrent hypersensitivity to PSC 833 or cyclosporine A.&#xD;
&#xD;
        Endocrine Therapy: Not specified.&#xD;
&#xD;
        Radiotherapy: No prior radiation therapy within 4 weeks of study.&#xD;
&#xD;
        Surgery: No major surgery within 4 weeks of study.&#xD;
&#xD;
        Other: No concurrent treatments that interfere with cyclosporine blood concentrations.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age: 18 and over.&#xD;
&#xD;
        Performance Status: ECOG 0-2.&#xD;
&#xD;
        Life Expectancy: At least 16 weeks.&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
        ANC greater than or equal to 1500/mm(3);&#xD;
&#xD;
        Platelet count greater than or equal to 100,000/mm(3).&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
        Bilirubin no greater than 1.5 x normal;&#xD;
&#xD;
        AST no greater than 2.5 x normal.&#xD;
&#xD;
        Renal:&#xD;
&#xD;
        Creatinine no greater than 2.0 mg/dL OR;&#xD;
&#xD;
        Creatinine clearance greater than or equal to 50 mL/min.&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
        No concurrent angina or myocardial infarction that has not been appropriately treated.&#xD;
&#xD;
        Other:&#xD;
&#xD;
        Not pregnant or nursing.&#xD;
&#xD;
        Effective contraceptive required of all fertile patients.&#xD;
&#xD;
        Patients with a history of curatively treated basal cell or squamous cell carcinoma are&#xD;
        eligible.&#xD;
&#xD;
        No HIV seropositivity.&#xD;
&#xD;
        No chronic hepatitis or cirrhosis.&#xD;
&#xD;
        Patients with concurrent reversible conditions such as diabetes, hypercalcemia,&#xD;
        hyperuricemia, hyperviscosity, infection, renal disease, or spinal cord compression are&#xD;
        eligible with appropriate therapy.&#xD;
&#xD;
        Patients must give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Cancer Institute (NCI)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chapman AE, Goldstein LJ. Multiple drug resistance: biologic basis and clinical significance in renal-cell carcinoma. Semin Oncol. 1995 Feb;22(1):17-28. No abstract available.</citation>
    <PMID>7855615</PMID>
  </reference>
  <reference>
    <citation>Boote DJ, Dennis IF, Twentyman PR, Osborne RJ, Laburte C, Hensel S, Smyth JF, Brampton MH, Bleehen NM. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol. 1996 Feb;14(2):610-8. doi: 10.1200/JCO.1996.14.2.610.</citation>
    <PMID>8636778</PMID>
  </reference>
  <reference>
    <citation>Twentyman PR. MDR1 (P-glycoprotein) gene expression--implications for resistance modifier trials. J Natl Cancer Inst. 1992 Oct 7;84(19):1458-60. doi: 10.1093/jnci/84.19.1458. No abstract available.</citation>
    <PMID>1359150</PMID>
  </reference>
  <verification_date>January 2000</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Cytochrome P 450</keyword>
  <keyword>Multi-Drug Resistance</keyword>
  <keyword>P-Glycoprotein</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

